Confirmation of a mechanistic link between FGF signalling and the DNA damage response would not only rationalise the influence of individuality in FGF1 expression on disease progression and chemotherapy response in ovarian cancer patients, but may additionally identify candidate resistance biomarkers and novel combination chemotherapy/resistance pathway inhibitor approaches for future clinical trial evaluation. The gene discussed is FGF1; the disease is ovarian cancer.